Rs 150 per dose not sustainable: Bharat Biotech demands higher price for Covaxin from Centre

Bharat Biotech has so far invested over Rs 500 crores at risk from its own resources for product development, clinical trials and setting up of manufacturing facilities for Covaxin.

from Zee News :India National https://ift.tt/35lNZgr

• Tweet
• Share
• Share
• Share
• Share